Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Yue-ping Jia"'
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-3 (2024)
Externí odkaz:
https://doaj.org/article/dbec8d46bec347348c487b86c9e67c40
Publikováno v:
Frontiers in Oncology, Vol 13 (2024)
IntroductionThe prognostic role of Wilms’ tumor 1 (WT1) gene expression at diagnosis in children with B cell precursor acute lymphoblastic leukemia (BCP-ALL) is still controversial.MethodsWe detected the WT1 transcript levels of 533 de novo pediatr
Externí odkaz:
https://doaj.org/article/122e9ef697b74e74ac2b632a73e85329
Autor:
Guan-hua Hu, Yi-fei Cheng, Ai-dong Lu, Yu Wang, Ying-xi Zuo, Chen-hua Yan, Jun Wu, Yu-qian Sun, Pan Suo, Yu-hong Chen, Huan Chen, Yue-ping Jia, Kai-yan Liu, Wei Han, Lan-ping Xu, Le-ping Zhang, Xiao-jun Huang
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background Pediatric acute myeloid leukemia (AML) with t(8;21) (q22;q22) is classified as a low-risk group. However, relapse is still the main factor affecting survival. We aimed to investigate the effect of allogeneic hematopoietic stem cel
Externí odkaz:
https://doaj.org/article/b4dc714a28e140b080eb6251de92151d
Autor:
Guan-hua Hu, Yi-fei Cheng, Ying-xi Zuo, Ying-jun Chang, Pan Suo, Jun Wu, Yue-ping Jia, Ai-dong Lu, Ying-chun Li, Yu Wang, Shun-chang Jiao, Long-ji Zhang, Xiang-yu Zhao, Chen-hua Yan, Lan-ping Xu, Xiao-hui Zhang, Kai-yan Liu, Le-ping Zhang, Xiao-jun Huang
Publikováno v:
Frontiers in Immunology, Vol 12 (2022)
BackgroundThe presence of minimal residual disease (MRD) is an independent risk factor for poor prognosis in patients with acute lymphoblastic leukemia (ALL). Moreover, the role of chimeric antigen receptor T-cell (CAR-T) therapy in patients with MRD
Externí odkaz:
https://doaj.org/article/af3c56d9f626408f844f712ad374a2b1
Publikováno v:
Frontiers in Oncology, Vol 10 (2021)
PurposeWhile the role of minimal residual disease (MRD) assessment and the significance of achieving an MRD-negative status during treatment have been evaluated in previous studies, there is limited evidence on the significance of MRD re-emergence wi
Externí odkaz:
https://doaj.org/article/9480e1472d4f476baff34f991988474e
Publikováno v:
Cancer Research & Treatment; Jul2024, Vol. 56 Issue 3, p945-955, 11p
Autor:
Yu-juan Xue, Yu Wang, Ai-dong Lu, Yue-ping Jia, Ying-xi Zuo, Ming-ming Ding, Hui-min Zeng, Le-ping Zhang
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2be5d7333ed9a91a0f799d46936bfce7
https://doi.org/10.1016/j.clml.2023.03.013
https://doi.org/10.1016/j.clml.2023.03.013
Autor:
Hui Sun, Runhui Wu, Li Meng, Hai Lin, Zesheng Lu, Le-Ping Zhang, Yue-Ping Jia, Yanli Zhang, Fang-Yuan Zheng, Jie Jin, Liqiang Zhang, Li Zhou, Xuelin Dou, Wei Yang, Qian Jiang, Si-Xuan Qian, Hongxia Ma, Xiaofan Zhu, Huilan Liu, Xielan Zhao, Bingcheng Liu
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 148:341-350
This study aimed to explore the health-related quality of life (HRQoL) and associated variables in children with chronic myeloid leukemia in the chronic phase (CML-CP) receiving tyrosine kinase inhibitors (TKIs). A cross-sectional questionnaire was g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20212f1710d27810172cd59bd6401ef9
https://doi.org/10.1007/s00432-021-03832-y
https://doi.org/10.1007/s00432-021-03832-y
Autor:
Xiaofan Zhu, Li Zhou, Xuelin Dou, Zhilin Jia, Yue-Ping Jia, Hongxia Ma, Si-Xuan Qian, Huilan Liu, Xielan Zhao, Fanjun Meng, Qingxian Bai, Haixia Di, Wei Yang, Zesheng Lu, Hai Lin, Le-Ping Zhang, Na Xu, Jie Jin, Li Meng, Bingcheng Liu, Fang-Yuan Zheng, Yanli Zhang, Liqiang Zhang, Qian Jiang, Xin Du, Hui Sun
Publikováno v:
Annals of Hematology. 100:2215-2228
To explore the differences in the clinical features, treatment responses, and outcomes among children, adolescents, and adults with chronic myeloid leukemia in the chronic phase (CML-CP) receiving imatinib as first-line therapy. Data from children (0
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e008f661a3db17c6678f76c4454ee874
https://doi.org/10.1007/s00277-021-04544-6
https://doi.org/10.1007/s00277-021-04544-6
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e301-e308
Background Acute megakaryoblastic leukemia (AMKL) is a biologically heterogeneous subtype of acute myeloid leukemia that originates from megakaryocytes. Patients with AMKL with non-Down syndrome (DS) had a poorer prognosis. However, clear prognostic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1df30ff8cb030936a9afa1ae32942529
https://doi.org/10.1016/j.clml.2020.11.001
https://doi.org/10.1016/j.clml.2020.11.001